Amarin Corp Plc (AMRN)

[ziploc_1]

TalShu...Thank you for this instructive post...It has been almost a year since Steve Ketchum said in August 2022...“THE FIXED DOSE COMBINATION OR FDC PRODUCT IS IN THE EARLY STAGES OF DEVELOPMENT....IF SUCCESSFUL, THE COMBINATION THERAPY WOULD BE A GAME-CHANGER for patients since it will carry the most significant cardiovascular risk outcome benefit label AND WOULD HOPEFULLY PROVIDE ADDITIONAL MARKET EXCLUSIVITY”

Ketchum's field is research, not marketing...Berg's field, however, is marketing...Perhaps Berg, in consort with Amarin's legal department, could provide some guidance about the 'ADDITIONAL MARKET EXCLUSIVITY' remark of Ketchum...Does Amarin have a patent on a FDC?....Would the exclusivity depend on a FDC being a new product?...even without exclusivity, a FDC would still carry the 'significant cardiovascular risk outcome benefit' label....as opposed to the generics, which do not have approval for CVD reduction.